University of Michigan Rogel Cancer Center — Biomedical Watch V2

Essais liés8clinical trials

VilleAnn Arborlocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07198074

Ouvrir le site du centre

Essais cliniques associés

8

Molécule	Indication / population	Phase	NCT	Titre	Statut
Biospecimen Collection	Cancer	Phase 3	NCT07097142	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study	RECRUITING
Bevacizumab	Cancer	Phase 3	NCT07198074	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	RECRUITING
Biopsy Procedure	SEP	Phase 2	NCT02143414	Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia	ACTIVE_NOT_RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING
Biopsy Procedure	Cancer	Phase 1	NCT05630794	Testing for Safety and Colorectal Cancer Preventive Effects of ONC201	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06337318	Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT05256225	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma	RECRUITING
Bone Scan	Cancer	Phase 2/3	NCT05691478	A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma	SUSPENDED